ArticleRegenerative therapy2026
Design and initial evaluation of a certified committee model for review of in vivo gene therapy and related technologies, together with ex vivo gene therapy, under the act on the safety of regenerative medicine.
Article in Regenerative therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The 2024 amendment to the Act on the Safety of Regenerative Medicine expanded the Act's regulatory scope to include in vivo gene therapy and related technologies. This created a need for certified committees for regenerative medicine to address associated scientific and regulatory issues. This study aimed to design and provide an initial evaluation of a practical and implementable committee model for reviewing newly covered technologies and ex vivo gene therapy under the amended Act. Methods: We conducted an institutional implementation study to develop a dual-committee model consisting of an independent second committee for gene therapy review, supported by selected shared foundational functions from an existing cell-based therapy committee. The success of the initial implementation was prospectively evaluated at the first review meeting using five predefined items: committee establishment, organizational structure, membership composition, workflow establishment, and operational feasibility. Results: A newly established specific certified committee for regenerative medicine for gene therapy review was certified by the Ministry of Health, Labour and Welfare on November 28, 2025. The predefined organizational model was implemented as an independent second committee with a shared institutional foundation. The required membership categories were fulfilled, including those specific to gene therapy review. A standardized review workflow incorporating prior administrative checks and a preliminary document review was established and successfully applied at the first review meeting, without major procedural disruption. Conclusions: A dual-committee model combining an independent second committee with a shared institutional foundation provided a practical and operationally feasible approach for implementing gene therapy review capacity within an existing regenerative medicine review infrastructure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.